Amgen’s Kyprolis found to increase cancer survival rate
A Phase 3 clinical study of Amgen’s multiple myeloma drug Kyprolis showed that it increased overall survival rate when paired with lenalidomide and dexamethasone versus just those two drugs alone. The drug reduced the risk of death by 21 percent, and patients lived 7.9 months longer when on a regimen that included Kyprolis than those Read More →
Read More →Frontier Communications completes 1-for-15 reverse stock split
Frontier Communications completed a 1-for-15 reverse stock split on July 10, opening at $16.35 per share, with around 175 million shares outstanding. The company announced the split March 28 when it filed paperwork with the Securities and Exchange Commission, and the move was approved by shareholders and the board of directors May 10. Its market Read More →
Read More →Sienna Biopharmaceuticals files for $75 million IPO
Westlake Village biotechnology company Sienna Biopharmaceuticals filed for an initial public offering with the Securities and Exchange Commission on June 3, stating expectations to raise up to $74.75 million. Founded in 2010, the company develops clinical-stage topical therapies for inflammatory skin diseases and other conditions. ARCH Venture Partners and Venvest Capital led a $40 million Read More →
Read More →Semtech acquires AptoVision Technologies
Semtech, a semiconductor and Internet of Things company based in Camarillo, signed a $28 million agreement to acquire AptoVision Technologies, a chip maker for high-definition displays based in Montreal. Semtech plans to finance the deal with cash on hand, including additional contingent payments of up to $47 million based on future financial targets, according to Read More →
Read More →Activist investor demands that Deckers Brands sell company
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →